Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors

AIDS

Volumn 12, Issue 6, 1998, Pages 613-618

  Walsh, John C ^a   Jones, Colin D ^a   Barnes, Eric A ^a   Gazzard, Brian G ^a   Mitchell, Suzanne M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Cytomegalovirus; Natural history; Protease inhibitors; Retinitis; Survival; Therapy

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETINITIS; SURVIVAL;

EID: 0032537169     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199806000-00010     Document Type: Article

References (40)

1. Connors M, Kovacs JA, Krevat S, et al.: HIV infection induces changes in CD4+ T cell phenotype and depletions within the CD4+ T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997, 3:533-540.
2. Bloom JN, Palestine AG: The diagnosis of cytomegalovirus retinitis. Ann Intern Med 1988, 109:963-969.
3. Palestine AG, Polis MA, De Smet MD, et al.: A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991, 115:665-673.
4. Centers for Disease Control and Prevention: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993, 269:729-730.
5. Holland GN, Gottlieb MS, Yee RD, Schanker HM, Pettit TH: Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol 1982, 93:393-402.
6. Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY: Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology 1983, 90:859-873.
7. Palestine AG, Rodrigues MM, Macher AM, et al.: Ophthalmic involvement in the acquired immunodeficiency syndrome. Ophthalmology 1984, 91:1092-1099.
8. Henderly DE, Freeman WR, Causey DM, Rao NA: Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987, 94:425-432.
9. Jacobson MA, O'Donnell JJ, Porteus D, Brodie HR, Feigal D, Mills J: Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy. Q J Med 1988, 67:473-486.
10. Jabs DA, Enger C, Bartlett G: Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989, 107:75-80.
11. Holland GN, Sison RF, Jatulis DE, Haslop MG, Sakamoto MJ, Wheeler NC: Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. Ophthalmology 1990, 97:204-211.
12. Gross JG, Bozzette SA, Mathews WC, et al.: Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 1990, 97:681-686.
13. Harb GE, Bacchetti P, Jacobson MA: Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet. AIDS 1991, 5:959-965.
14. Peters BS, Beck EJ, Anderson S, et al.: Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. J Infect 1991, 23:129-137.
15. Dhillon B, Maclean H, Eddyshaw D, Cheong J, Flegg P, Brettle R: Cytomegalovirus retinitis and AIDS in Edinburgh. Int J STD AIDS 1993, 4:339 341.
16. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992, 326:213-220.
17. Polis MA, de Smet MD, Baird BF, et al.: Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am J Med 1993, 94:175-180.
18. Jacobson MA, Causey D, Polsky B, et al.: A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis 1993, 168:444 448.
19. Drew WL, Ives D, Lalezari JP, et al.: Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995, 333:615-620.
20. Yust I, Burke M, Katlama C, et al.: Incidence and survival of patients with AIDS and CMV retinitis. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoC1459].
21. Murphy R, Palella F, Bonnet J, Bennett C, Phair J: Gender differences in rates of disease progression and survival in patients with AIDS and CMV retinitis. XI International Conference on AIDS. Vancouver, July 1996 [abstract WeC3413].
22. Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY: Acquired immune deficiency syndrome. Pathogenic mechanisms of ocular disease. Ophthalmology 1985, 92:472-484.
23. Kuppermann BD, Petty JG, Richman DD, et al.: Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related non-infectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993, 115:575-582.
24. Hoover DR, Saah AJ, Bacellar H, et al.: Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993, 329:1922-1926.
25. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE: Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992, 166:1223-1227.
26. d'Arminio Monforte A, Mainini F, Testa L, et al.: Predictors of cytomegalovirus disease, natural history and autopsy findings in a cohort of patients with AIDS. AIDS 1997, 11:517-524.
27. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group: Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995, 172:613-621.
28. Masur H, Whitcup SM, Cartwright C, Polis M, Nussenblatt R: Advances in the management of AIDS-related cytomegalovirus retinitis. Ann Intern Med 1996, 125:126-136.
29. Sandy CJ, Bloom PA, Waldron S, Migdal CS: Long survival in AIDS-related cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:209 210.
30. Fischl MA, Richman DD, Grieco MH, et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987, 317:185-191.
31. Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom free HIV infection. Lancet 1994, 343:871 881.
32. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996, 348:283 291.
33. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4+ cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
34. Saravolatz LD, Windslow DL, Collins G, et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4+ cells per cubic millimeter. N Engl J Med 1996, 335:1099 1106.
35. Salgo MP, Beattie D, Bragman K, et al.: Saquinavir (Invirase, SQV) vs. Hivid (zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take Retrovir (zidovudine, ZDV). XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB410].
36. Cameron DW, Heath-Chiozzi M, Kravcik S, et al.: Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB411].
37. 3: clinical efficacy. Eighth European Congress of Clinical Microbiology and Infectious Diseases. Lausanne, May 1997 [abstract LB 1502].
38. 3. Eighth European Congress of Clinical Microbiology and Infectious Diseases. Lausanne, May 1997 [abstract LB S90a].
39. Centers for Disease Contol and Prevention: Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR 1997, 46:165-173.
40. Hogg RS, O'Shaughnessy MV, Gataric N, et al.: Decline in deaths from AIDS due to new antiretrovirals [letter]. Lancet 1997, 349:1294.